Prognostic Value of Molecular Markers for Guiding Post-Remission Therapy in Patients with De Novo Acute Myeloid Leukemia (AML) and Intermediate-Risk Cytogenetics.

被引：0
|
作者：
Pratcorona, Marta [1 ]
Camos, Mireia [2 ]
Torrebadell, Montserrat [2 ]
Rozman, Maria [2 ]
Carrio, Ana [2 ]
Costa, Dolors [2 ]
Valera, Alexandra [2 ]
Campo, Elias [2 ]
Montserrat, Emili [1 ]
Esteve, Jordi [1 ]
机构：
[1] Univ Barcelona, IDIBAPS, Hosp Clin, Inst Hematol & Oncol,Dept Hematol, Barcelona, Spain
[2] Univ Barcelona, IDIBAPS, Hosp Clin, Hematopathol Unit, Barcelona, Spain
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：875 / 876
页数：2
相关论文
共 50 条
  • [1] The Value of Post-Remission Therapy in Older Adults with Acute Myeloid Leukemia (AML).
    Sekeres, Mikkael A.
    Fu, Alex Z.
    Earl, Marc
    Kalaycio, Matt
    Advani, Anjali
    Saunthararajah, Yogen
    Sobecks, Ronald
    Copelan, Edward
    BLOOD, 2009, 114 (22) : 431 - 432
  • [2] IMPACT OF MOLECULAR MARKERS ON THE OUTCOME OF ACUTE MYELOID LEUKEMIA WITH INTERMEDIATE-RISK CYTOGENETICS
    Hoyos, M.
    Brunet, S.
    Tormo, M.
    Ribera, J. M.
    Nomdedeu, J.
    Esteve, J.
    Llorente, A.
    Gallardo, D.
    Queipo de Llano, M. P.
    Duarte, R.
    Heras, I.
    Besalduch, J.
    Bargay, J.
    Marti, J. M.
    Pedro, C.
    Gonzalez, J.
    Font, L.
    Pratcorona, M.
    Oriol, A.
    Sierra, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 268 - 269
  • [3] A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia
    Torrebadell, Montserrat
    Diaz-Beya, Marina
    Kalko, Susana G.
    Pratcorona, Marta
    Nomdedeu, Josep
    Navarro, Alfons
    Gel, Bernat
    Brunet, Salut
    Sierra, Jorge
    Camos, Mireia
    Esteve, Jordi
    LEUKEMIA & LYMPHOMA, 2018, 59 (10) : 2394 - 2404
  • [4] Race and Intensity of Post-Remission Therapy in Acute Myeloid Leukemia (AML).
    Brady, Anna K.
    Fu, Alex Z.
    Earl, Marc
    Kalaycio, Matt
    Advani, Anjali
    Saunthararajah, Yogen
    Sobecks, Ronald
    Copelan, Edward
    Sekeres, Mikkael A.
    BLOOD, 2009, 114 (22) : 419 - 419
  • [5] The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status
    Diaz-Beya, Marina
    Rozman, Maria
    Pratcorona, Marta
    Torrebadell, Montserrat
    Camos, Mireia
    Aguilar, Joseph L. I.
    Esteve, Jordi
    BLOOD, 2010, 116 (26) : 6147 - 6148
  • [6] Bcl-xl expression as an adverse prognostic factor for remission induction in adult de novo AML patients with intermediate risk cytogenetics.
    Schaich, M
    Illmer, T
    Mohr, B
    Schäkel, U
    Beck, J
    Ehninger, G
    BLOOD, 2000, 96 (11) : 197B - 197B
  • [7] Prognostic risk assessment based on combined cytogenetics and molecular screening for optimal choice of post-remission therapy in patients with acute myeloid leukaemia
    Torrebadell, M.
    Camos, M.
    Pratcorona, M.
    Rozman, M.
    Rovira, M.
    Martinez, C.
    Fernandez-Aviles, F.
    Carrio, A.
    Costa, D.
    Montserrat, E.
    Carreras, E.
    Esteve, J.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S47 - S48
  • [8] Effective post-remission therapy with an autologous stem cell transplant (ASCT) for the ELN-favourable and intermediate-risk acute myeloid leukaemia (AML) patients
    Cerny, J.
    Ramanathan, M.
    Raffel, G.
    Evens, A.
    Walsh, W.
    Fortier, N.
    Shanahan, L.
    Bednarik, J.
    Rosmarin, A.
    Nath, R.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S538 - S539
  • [9] Assessment of CEBPA Mutations Might Contribute to a Better Prognostic Assignment in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia (AML).
    Pratcorona, Marta
    Torrebadell, Montserrat
    Villamor, Neus
    Rozman, Maria
    Camos, Mireia
    Carrio, Ana
    Costa, Dolors
    Beyaa, Marina Diaz
    Montserrat, Emili
    Esteve, Jordi
    BLOOD, 2009, 114 (22) : 1024 - 1025
  • [10] A randomized study of fludarabine in part of induction and post-remission treatment for de novo acute myeloid leukemia (AML) in elderly patients.
    Witz, F
    Harousseau, JL
    Sadoun, A
    Cahn, JY
    Le Prise, PY
    Tournilihac, O
    Desablens, B
    Guyotat, D
    Vilque, JP
    Berthou, C
    Solary, E
    Ojeda, M
    Casassus, P
    Francois, S
    Delain, M
    Dorvaux, V
    Raby, P
    Guibon, O
    Berthaud, P
    Liqure, B
    BLOOD, 2000, 96 (11) : 504A - 504A
12345